Skip to main content

Advertisement

SpringerLink
Log in

Significance of Her-2/neu protein over expression in Indian breast cancer patients

  • Original Article
  • Published:
Indian Journal of Surgery Aims and scope Submit manuscript

Abstract

Background

Racial disparity in presentation and outcome of breast cancer is established but cause is unexplained. Many studies show various molecular markers for racial differences in the prognosis of breast cancer. There is scarcity of data on prognostic significance of HER-2/neu in Indian breast cancer.

Aims and Objective

To know incidence and prognostic significance of HER-2/neu expression in Indian patients. To correlate HER-2/neu Expression with other prognostic markers and ER/PR Receptor status.

Material and Methods

112 consecutive patients with breast cancer attending the Department of Surgical Oncology from March 1997 to March 2000 were included in this study. The clinical data along with ER/PR status, follow up data and HER-2/neu expression examined by immuno-histochemical method was recorded.

Statistical Analysis

Data was analyzed by univariate and multivariate analysis for all prognostic factors. Significance was calculated by using Chi square test and survival analysis by using Kaplan Meier survival curve.

Results

The median age of 112 patients was 46.56 (±9.55) years. HER-2/neu over expression was present in 46.37%. Significant correlation was found between HER-2/neu over expression and lymph node status, grade of tumor and ER/PR receptor status. Median follow up period of 23 months. There was significant tumour free survival advantage (p < 0.01) and overall survival advantage (p < 0.001) in patients with HER-2/neu negative expression.

Conclusion

HER-2/neu oncogene over expression is higher (46.37%) among Indian patients in comparison to 25–30% shown in most western literature. HER-2/neu oncogene over expression significantly correlates with grade, lymph node involvement, ER/PR status and also affects survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rose DP, Royak-Schaler R (2001) Tumor biology and prognosis in black breast cancer patients: a review. Cancer Detect Prev 25:16–31

    PubMed  CAS  Google Scholar 

  2. Ikpatt OF, Kuopio T, Collon Y (2002) Proliferation in African breast cancer: biology and prognostication in Nigerian breast cancer material. Mod Pathol 15(1):78

    Google Scholar 

  3. Simon MS SR (1997) Racial differences in breast cancer survival. The interaction of socio-economic status and tumor biology. Am J Obstet Gynecol 176:233–236

    Article  Google Scholar 

  4. Cheng SH, Tsou MH, Liu MC (2000) Unique features of breast cancer in Taiwan. Breast Cancer Res Treat 63:213–223

    Article  PubMed  CAS  Google Scholar 

  5. Chow LW TA, Cheung KL, Au GK (1997) Current status of breast cancer in Hong Kong. Chin Med (Engl) 110:474–478

    CAS  Google Scholar 

  6. Ezzat A RM, Zwaan F, Brigden M (1998) The lack of age as a significant prognostic factor in non-metastatic breast cancer. Eur J Surg Oncol 24:23–27

    Article  PubMed  CAS  Google Scholar 

  7. Fakhro AE FB, Al-Asheeri N, Al-Ekri SA (1999) Breast cancer. Patient characteristics and survival analysis at Salmaniya Medical Complex, Bahrain. Eastern Mediterranean Health Journal 5:430–439

    PubMed  CAS  Google Scholar 

  8. Maalej M FH, Ben Salem S, Daoud J (1999) Breast cancer in Tunisia: clinical and epidemiological study. Bull Cancer 86:302–306

    PubMed  CAS  Google Scholar 

  9. Malik IA (2002) Clinico-pathological features of breast cancer in Pakistan. J Pak Med Assoc 52:100–104

    PubMed  CAS  Google Scholar 

  10. Salmon DJ, deKernion JB, Verma IM (1984) Expression of cellular oncogenes in human malignancies. Science 224:256–262

    Article  Google Scholar 

  11. Bankfalvi A, Tory K, Kemper M. (2000) Clinical relevance of immunohistochemical expression of p53-targeted gene product mdm-2, p21 and bcl-2 in breast carcinoma. Pathol Res Pract 196:489–501

    PubMed  CAS  Google Scholar 

  12. Barbareschi M, Caffo O, Veronese S (1996) Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol 27: 1149–1155

    Article  PubMed  CAS  Google Scholar 

  13. Ferrero-Pous M, Hacene K, Bouchet C, Le Doussel V, Tubiana Hulin M, Spyratus F (2000) Relationship between c-erbB-2 and other tumor characteristics in breast cancer prognosis. Clin Cancer Res 6:4745–4754

    PubMed  CAS  Google Scholar 

  14. Jansen RL, Joosten-Achjanie SR, Volovics A (1998) Relevance of the expression of bcl-2 in combination with p53 as a prognostic factor in breast cancer. Anticancer Res 18:4455–4462

    PubMed  CAS  Google Scholar 

  15. Nunes RA, Harris LN (2002) The HER-2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer 3:125–135

    PubMed  Google Scholar 

  16. Ross JS, Fletcher JA (1998) The HER-2/ neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Stem Cells 16:413–428

    Article  PubMed  CAS  Google Scholar 

  17. Sahin AA (2000) Biologic and clinical significance of HER-2/neu (cerB-2) in breast cancer. Adv Anat Pathol 7:158–166

    Article  PubMed  CAS  Google Scholar 

  18. Bhatavdekar JM, Patel DD, Shah NG, Vora HH, Suthar TP, Chikhikar PR, et al. (2000) Prognostic significance of immunohistochemically localized biomarkers in stage II and stage III breast cancer: a multivariate analysis. Annals of Surgical Oncology 7:4305–4311

    Article  Google Scholar 

  19. The World Health Organization Histological Typing of Breast Tumor, (1982) 2nd ed. Am J Pathol 78:806

    Google Scholar 

  20. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long term follow up. Histopathology 20:479–489

    Google Scholar 

  21. Perren TJ (1991) C-ErbB-2 oncogene as a prognostic marker in breast cancer. Br J Cancer 63:328–332

    PubMed  CAS  Google Scholar 

  22. Aryandono T, Harijadi, Ghozali A (2000) Correlation of clinical, pathologica status, hormone receptor and C-ErbB-2 oncoprotein in breast cancer patients. Gan-To-Kagaku-Ryoho Suppl 2:600–606

    Google Scholar 

  23. Looi-LM, Cheah-PL (1998) C-ErbB-2 oncoprotein amplification in infiltrating ductal carcinoma of breast relates to high histological grade and loss of oestrogen receptor protein. Malays J Pathol 20:19–23

    PubMed  CAS  Google Scholar 

  24. Tandon H, Clark GM, Chamness GC (1989) HER-2/neu oncogene protein and prognosis in breast cancer. J Clin Onco 17:1120–1128

    Google Scholar 

  25. Bames DM, Millis RR (1995) Oestrogen Receptors. The history relevance and the method of evaluation. In progress in pathology. Vol. 2 Kirkhan N, Lemoine N (eds), London Churchill Livingston

    Google Scholar 

  26. Traina A, Agostara B, Marasa L, Calabro M, Zarcone M, Carruba G (2006) HER2/neu expression in relation to clinicopathologic features of breast cancer patients. Ann N Y Acad Sci 1089:159–167

    Article  PubMed  CAS  Google Scholar 

  27. Ciocca DR, Gago FE, Fanelli MA, Calderwood SK (2006) Co-expression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) andHer-2/neu:Clinical, implications. J Steroid Biochem Mol Biol 02(1–5):32–40

    Article  CAS  Google Scholar 

  28. Egervari K, Szollosi Z, Nemes Z (2007) Tissue microarray technology in breast cancer HER2 diagnostics. Pathol Res Pract 203:169–177

    Article  PubMed  Google Scholar 

  29. Ferretti G, Felici A, Papaldo P, Fabi A, Cognetti F (2007) HER2/neu role in breast cancer: from a prognostic foe to a predictive friend. Curr Opin Obstet Gynecol 19(1):56–62

    Article  PubMed  Google Scholar 

  30. Rakha EA, El-Sayed ME, Green AR, Lee AH, Robertson JF, Ellis IO (2007) Prognostic markers in triple negative breast cancer. Cancer 109(1):25–32

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Institute of Medical Sciences, Banaras Hindu University, 7 SKG Colony, Lanka, Varanasi, 221 005, India

    Vikash Kumar, Mallika Tewari & H. S. Shukla

  2. Department of Pathology, Institute of Medical Sciences, Banaras Hindu University, 7 SKG Colony, Lanka, Varanasi, 221 005, India

    Usha Singh

Authors
  1. Vikash Kumar
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mallika Tewari
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Usha Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. H. S. Shukla
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kumar, V., Tewari, M., Singh, U. et al. Significance of Her-2/neu protein over expression in Indian breast cancer patients. Indian J Surg 69, 122–128 (2007). https://doi.org/10.1007/s12262-007-0002-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12262-007-0002-8

Keywords

Search

Navigation